Quercis Pharma AG is a private Swiss biotech company advancing a novel antithrombotic in multiple indications: the lead program is prevention of Venous Thrombosis Embolism in advanced cancer patients (phase III) followed by clinical trials in Sickle Cell Disease (phase II) and Covid-19 (phase II).